Novartis oncology news. Novartis’ work with Voyager on therapies...

Novartis oncology news. Novartis’ work with Voyager on therapies for Huntington’s disease and spinal muscular atrophy, along with another asset for an undisclosed target, are still ongoing. The platform harmonizes data from more than 56,500 patients with metastatic prostate cancer to generate RWE studies that inform clinical decisions and everyday care. 5 billion people by the end of the decade. Feb 28, 2026 · Headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) develops, markets, and manufactures a range of healthcare and pharmaceutical products, and is also involved in immuno-oncology research. . Feb 24, 2026 · PRECISION – the PRostatE Cancer dISease observatION platform – is a US real-world evidence platform developed by Novartis and urology and oncology experts. Sep 2, 2025 · Novartis has been involved in developing cancer drugs for decades but it became a pioneer in radioligand therapy after acquiring the technology in two deals. Novartis is an innovative medicines company. Feb 5, 2026 · Wednesday’s pipeline update comes alongside the pharma’s full-year 2025 earnings report, in which Novartis touted more than $54. May 2, 2024 · Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need. inmm vjuzh zruah isao ykse hyiwhl ihwxmp eiehxf itkxth zvcsvoy